PHC Corporation Wins 2025 R&D 100 Award
The Biomedical Division of PHC Corporation has been recognized with a 2025 R&D 100 Award for its groundbreaking live cell metabolic pathway analyzer, LiCellMo. Launched in Japan in September 2024 and expanded globally the following month, LiCellMo delivers continuous, real-time insights into key cellular metabolic pathways. This innovation gives researchers unprecedented visibility into dynamic cell state changes, supporting discoveries and advancing therapeutic development.
PHC Corporation Wins 2025 R&D 100 Award